Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE).
Treatment of acute PE is traditionally hospital based and associated with high costs. The …

Direct oral anti-coagulants (DOACs) reduce hospital length-of-stay (LOS) in patients with
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …

Anticoagulant treatment of acute pulmonary embolism (PE) has traditionally been hospital-
based. The lesser need for monitoring with the increasingly used direct acting oral …

Background Clinical guidelines have supported outpatient treatment of low‐risk pulmonary
embolism (PE) since 2014, but adoption of this practice has been slow. Direct oral …

Direct-acting oral anticoagulants (DOACs) are prescribed in the treatment of venous
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …

Background Data regarding the use of direct oral anticoagulants (DOACs) for the treatment
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …

Dose adjustment of direct oral anticoagulants (DOACs) is not required in the setting of acute
PE treatment according to the manufacturer's labelling, beyond the contraindication in …

Objectives The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …

Introduction Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but
is under-represented in trials of direct oral anticoagulants (DOACs) in venous …

Pulmonary embolism (PE) represents a potentially life-threatening venous thromboembolic
disorder, and prompt treatment is vital to prevent early mortality. However, diagnosis of PE is …